Choose IndicationDrugDrug name X NVAF Reduce stroke risk PAD Reduce the risk of major thrombotic vascular events CAD Reduce the risk of major CV events VTE Prophylaxis Acutely Ill Medical Patients DVT/PE Initial treatment DVT/PE Extended treatment DVT Prophylaxis After hip/knee replacement surgery Home Clinical Trial Efficacy Profile Safety Profile Dosing Home Clinical Trials Efficacy Safety Net Clinical Benefit Summary Dosing Home Clinical Trials Efficacy Profile Safety Profile Dosing Home Clinical Trials Efficacy Profile Safety Profile Dosing Home Clinical Trial Efficacy Profile Safety Profile Dosing Home Clinical Trials Efficacy Profile Safety Profile Dosing Home Clinical Trial Efficacy Profile Safety Profile Dosing Dosing NVAF CAD/PAD DVT/PE Switch and Management Switching to/from XARELTO® Bleed management considerations Temporary discontinuation Other administration Access and Support Janssen Select Janssen CarePath Formulary Finder Prescription Assistance Request XARELTO® samples Resources Resources Hub FAQs Search Important Safety Information US Prescribing Information Medication Guide For Non-US Visitors Patient Site SEARCH For Choose Indication NVAFReduce stroke risk PADReduce the risk of major thrombotic vascular events CADReduce the risk of major CV events VTE ProphylaxisAcutely Ill Medical Patients DVT/PEInitial treatment DVT/PEExtended treatment DVT ProphylaxisAfter hip/knee replacement surgery
Healthcare provider and patient resources Glossary Search x For your practice Tools and support: DOSING OVERVIEW Condition-specific dosing for XARELTO® JANSSEN MD® PROFESSIONAL INFORMATION RESOURCE Access to scientific and clinical information and services for Janssen products, including XARELTO® PIView the full Prescribing Information for XARELTO® STARTER PACK FOR DVT/PE 30-day Starter Pack after 6 months of initial treatment REPRINTS View XARELTO® clinical trials and studies Contact a Rep: REQUEST AN MSL Schedule time with an MSL REQUEST A REP Schedule time with a Rep For your patients Patient Savings and Financial Assistance: JANSSEN SELECT AFFORDABILITY PROGRAM Direct-to-patient affordability program to address coverage gaps JANSSEN CAREPATH SAVINGS PROGRAM For eligible patients with commercial insurance and an approved chronic condition JANSSEN CAREPATH SUPPORT FOR XARELTO® ENROLLMENT Get savings and support for XARELTO® JJPAF To help eligible patients receive prescription products Welcome Kits: NVAF PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for NVAF DVT/PE PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for DVT/PE CAD/PAD PATIENT BROCHURE Your patient’s guide to starting treatment for CAD/PAD ORS PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for ORS CAD = coronary artery disease; DVT = deep vein thrombosis; NVAF = nonvalvular atrial fibrillation; ORS = orthopedic (hip or knee) replacement surgery; PAD = peripheral artery disease; PE = pulmonary embolism. XARELTO® reprints Filter by Indication NVAF CAD PAD VTE Prophylaxis DVT/PE Initial DVT/PE Extended DVT/PE Prophylaxis NVAF: ROCKET AF Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial END-STAGE RENAL DISEASE (ESRD) Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis CAD: COMPASS Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease COMPASS (CAD SUBGROUP) Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial COMPASS (RISK STRATIFICATION) Steffel J et al. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared to aspirin in patients with chronic vascular disease COMPASS (DIABETES SUBGROUP) Bhatt DL et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease PAD: COMPASS (PAD SUBGROUP) Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial VOYAGER Bonaca MP et al. Rivaroxaban in peripheral artery disease after revascularization [article and supplementary appendix] VTE Prophylaxis: MAGELLAN (SUBGROUP) FOR ACUTELY ILL MEDICAL PATIENTS Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study DVT/PE Initial: EINSTEIN DVT The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism EINSTEIN PE The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism POOLED EINSTEIN DVT AND PE Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE randomized studies EINSTEIN CANCER SUBGROUPS Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN DVT and EINSTEIN PE) DVT/PE Extended: EINSTEIN CHOICE EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism DVT/PE Prophylaxis: RECORD1 Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty RECORD2 Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial RECORD3 Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty All resources For your practice Contact a Rep Tools and support For your patients Patient savings and financial assistance Patient welcome kits XARELTO® reprints NVAF CAD PAD VTE Prophylaxis DVT/PE Initial DVT/PE Extended DVT/PE Prophylaxis DOSING OVERVIEW Condition-specific dosing for XARELTO® REQUEST AN MSL Schedule time with an MSL REQUEST A REP Schedule time with a Rep JANSSEN MD® PROFESSIONAL INFORMATION RESOURCE Access to scientific and clinical information and services for Janssen products, including XARELTO® PIView the full Prescribing Information for XARELTO® STARTER PACK FOR DVT/PE 30-day Starter Pack after 6 months of initial treatment JANSSEN SELECT AFFORDABILITY PROGRAM Direct-to-patient affordability program to address coverage gaps JANSSEN CAREPATH SAVINGS PROGRAM For eligible patients with commercial insurance and an approved chronic condition JANSSEN CAREPATH SUPPORT FOR XARELTO® ENROLLMENT Get savings and support for XARELTO® CARE4TODAY® CONNECT A helpful medication and appointment-tracking and reminder tool designed to empower users to take an active role in their own health care NVAF PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for NVAF DVT/PE PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for DVT/PE CAD/PAD PATIENT BROCHURE Your patient's guide to starting treatment for CAD/PAD ORS PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for ORS PATIENT AFFORDABILITY OPTIONSSupport for your patient’s treatment JJPAF To help eligible patients receive prescription products ROCKET AF Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial END-STAGE RENAL DISEASE (ESRD) Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis COMPASS Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease COMPASS (CAD SUBGROUP) Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial COMPASS (RISK STRATIFICATION) Steffel J et al. The COMPASS trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared to aspirin in patients with chronic vascular disease COMPASS (DIABETES SUBGROUP) Bhatt DL et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease COMPASS (PAD SUBGROUP) Anand SS et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial VOYAGER Bonaca MP et al. Rivaroxaban in peripheral artery disease after revascularization [article and supplementary appendix] MAGELLAN (SUBGROUP) FOR ACUTELY ILL MEDICAL PATIENTS Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study EINSTEIN DVT The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism EINSTEIN PE The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism POOLED EINSTEIN DVT AND PE Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE randomized studies EINSTEIN CHOICE EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism EINSTEIN CANCER SUBGROUPS Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN DVT and EINSTEIN PE) RECORD1 Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty RECORD2 Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial RECORD3 Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty No results found for [no-term]. DOSING OVERVIEW Condition-specific dosing for XARELTO® REQUEST AN MSL Schedule time with an MSL REQUEST A REP Schedule time with a Rep JANSSEN MD® PROFESSIONAL INFORMATION RESOURCE Access to scientific and clinical information and services for Janssen products, including XARELTO® PIView the full Prescribing Information for XARELTO® STARTER PACK FORDVT/PE 30-day Starter Pack after 6 months of initial treatment JANSSEN SELECT AFFORDABILITY PROGRAM Direct-to-patient affordability program to address coverage gaps JANSSEN CAREPATH SAVINGS PROGRAM For eligible patients with commercial insurance and an approved chronic condition JANSSEN CAREPATH SUPPORT FOR XARELTO® ENROLLMENT Get savings and support for XARELTO® CARE4TODAY® CONNECT A helpful medication and appointment-tracking and reminder tool designed to empower users to take an active role in their own health care NVAF PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for NVAF DVT/PE PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for DVT/PE CAD/PAD PATIENT BROCHURE Your patient’s guide to starting treatment for CAD/PAD ORS PATIENT WELCOME KIT BROCHURE Your patient’s guide to starting treatment for ORS PATIENT AFFORDABILITY OPTIONSSupport for your patient’s treatment JJPAF To help eligible patients receive prescription products ROCKET AF Patel MR et al. Rivaroxaban versus warfarin in nonvalvular trial END-STAGE RENAL DISEASE (ESRD) Dias C et al. Pharmacokinetics, pharmacodynamics, and safety of single-dose rivaroxaban in chronic hemodialysis COMPASS Eikelboom JW et al. Rivaroxaban with or without aspirin in stable cardiovascular disease COMPASS (CAD SUBGROUP) Connolly SJ et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomized, double-blind, placebo-controlled trial COMPASS (RISK STRATIFICATION) Anand SS et al. Rivaroxaban plus aspirin versus aspirin in relation to vascular risk in the COMPASS trial COMPASS (DIABETES SUBGROUP) Bhatt DL et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease VOYAGER Anand SS et al . Rivoraxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety COMPASS SUBGROUP Anand SS et al. Rivoraxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomized, double-blind, placebo-controlled trial MAGELLAN (SUBGROUP) FOR ACUTELY ILL MEDICAL PATIENTS Spyropoulos AC et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study EINSTEIN DVT The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism EINSTEIN PE The EINSTEIN PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism POOLED EINSTEIN DVT AND PE Prins MH et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE randomized studies EINSTEIN CANCER SUBGROUPS Prins MH et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE) EINSTEIN CHOICE EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism RECORD1 Eriksson BI et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty RECORD2 Kakkar AK et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial RECORD3 Lassen MR et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
